A polo-like kinase inhibitor identified by computational repositioning attenuates pulmonary fibrosis.

ABSTRACT:

Background

Idiopathic pulmonary fibrosis (IPF) is a fatal fibrotic lung disease with few effective therapeutic options. Recently, drug repositioning, which involves identifying novel therapeutic potentials for existing drugs, has been popularized as a new approach for the development of novel therapeutic reagents. However, this approach has not yet been fully utilized in the field of pulmonary fibrosis.

Methods

The present study identified novel therapeutic options for pulmonary fibrosis using a systematic computational approach for drug repositioning based on integration of public gene expression signatures of drug and diseases (in silico screening approach).

Results

Among the top compounds predicted to be therapeutic for IPF by the in silico approach, we selected BI

SUBMITTER: Imakura T 

PROVIDER: S-EPMC10236721 | biostudies-literature | 2023 Jun

REPOSITORIES: biostudies-literature